FDA rejects Allarity's cancer candidate, demands more data

Allarity Therapeutics has received a firm no for its cancer drug candidate and its companion diagnostic device, dovitinib and DRP-Dovitinib, from the US health authority. A resubmission will require dialog with the FDA, the company says.

Allarity Therapeutics is off to a bad start with getting cancer drug dovitinib approved by the FDA | Photo: Allarity Therapeutics / PR

The US Food and Drug Administration (FDA) has rejected Allarity Therapeutics’s marketing application for the cancer drug dovitinib and its accompanying diagnostics tool, DRP-dovitinib, a company press release reported late Friday night.

The applications were submitted on April 9 and December 22 last year, respectively, but the FDA has now determined that the data provided is insufficient, as it does ”not enable a conclusion of efficacy based on non-inferiority data set,” per the press release. The company gives no further details pertaining to what the FDA found inadequate about the filing.

Now, Allarity Therapeutics is strategizing about a new prospective clinical trial to ”overcome the FDA’s outstanding objections,” and the company says that it intends to seek immediate guidance from the agency to resolve the issues, paving the way for a resubmission.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs